Get started
PFIZER INCPFIZER INCPFIZER INC

PFIZER INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

WHETHER 200-EMA WILL STOP THE PHIZEZ SLIDING MODE?The Pfizer Inc. Stock has been in a sliding mode since August when it hit its all-time high at $51.84 per share. However, the slide was stopped yesterday from strong support 200-period Exponential moving average and 38.2 Fibo level, which prevented the stock from drifting lower. Overall, the stock continues to trade below the downside line taken from the high of September 7th, which keeps the short-term outlook negative. However, in order to get confident on a trend continuation, the experts would like to see a dip below $41.50. A decisive break below that barrier would confirm a forthcoming lower low and may initially target the $38.15 per share hurdle, defined as a support by the 23.6 Fibo corrections. If investors are not willing to buy near that price, then the price could experience declines towards the $33.44 area, which acted as a temporary floor for the stock between October 2020 and March 2021. Looking at our short-term oscillators, we see that the RSI moved lower but ticked up from slightly above 30, while the MACD, already negative, has just fallen below its trigger line. Both indicators detect downside speed, which enhances the case for further declines in this stock. The move that could change the short-term picture to positive is the subsequent rebound from 200-EMA and 38.2 corrections and a break above $42.65. This will confirm the break above the pre-mentioned downside line and a forthcoming higher high. The bulls may get encouraged to push the action towards the high around $44.84 or the peak of September 07th, at $47.52. If they don’t stop there, we could see them aiming for the all-time high above $50.00. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carry a high-risk level. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and such sites. Furthermore, one understands that the company carries zero influence over transactions, needs, and trading signals. Therefore, it cannot be held liable nor guarantee any profits or losses.
NYSE:PFE
by legacyFXofficial
Pfizer | Fundamental Analysis | Short view Many would agree that a half victory is better than a total defeat. Pfizer and BioNTech have seen this through firsthand experience. The two partners had hoped that an FDA advisory committee would recommend revaccination with the COVID-19 vaccine to all Americans 16 years of age and older. A week ago, however, the committee voted 16-2 against recommending the Pfizer-BioNTech vaccine for a wide age range. It wasn't just bad news for these drug companies, however. The FDA advisory committee also voted unanimously to recommend the boosters for U.S. citizens age 65 and older, and anyone at high risk for severe COVID-19. And now you're probably wondering, could Pfizer stock be a reasonable investment choice after this partial victory? The FDA still has to decide whether to revaccinate the Pfizer-BioNTech vaccine. If the agency follows the commission's recommendations and the Centers for Disease Control and Prevention (CDC) agrees with them, many additional vaccines could soon become available. As per the U.S. Department of Health and Human Services' Office on Aging, there were about 52.4 million Americans age 65 and older in 2018. Today, that number is undoubtedly higher. Vaccination rates among older Americans are higher than any other age group. According to the CDC, nearly 85 percent of people between the ages of 65 and 74 have been fully vaccinated. Nearly 80% of Americans age 75 and older have been fully vaccinated. We don't know how many of these people received the Comirnaty COVID-19 vaccine from Pfizer and BioNTech. However, overall, Comirnaty accounts for about 57% of all COVID-19 vaccine doses administered to date. It is estimated that about 25 million Comirnaty revaccinations could be administered in the following months if the FDA and CDC give the green light to revaccination. Based on previous vaccine prices, the total cost of revaccination for the groups recommended by the FDA panel could approach $500 million. At first glance, the possibility of an additional $500 million over the next few months may seem significant. However, there are several reasons not to get so excited. Most importantly, none of the companies are likely to get "extra" money from boosters shortly. The U.S. has already ordered a total of 500 million doses from Pfizer and BioNTech, plus another 500 million doses for transfer to other countries. At least at this time, it is doubtful that extra doses will be purchased by the government to vaccinate Americans. Keep in mind also that Pfizer and BioNTech share profits from Comirnaty. Even if the companies could expect additional orders from the U.S. government for boosters, the financial impact for Pfizer would not be huge. In the second quarter, the company had revenue of $19 billion and profits of nearly $5.6 billion. There is really no good reason to buy Pfizer stock based on the recommendation of the FDA advisory committee. Nevertheless, there are other reasons why investors might seriously consider stock in this major pharmaceutical company. The need for an annual refill for everyone is still a real possibility. If Pfizer can count on strong recurring revenues from Comirnaty for years to come, the stock will look much more attractive. No doubt, Pfizer doesn't just rely on its COVID-19 vaccine. The pharmaceutical giant has other growth drivers that should appeal to investors, notably the rare heart disease drug Vyndaqel/Vyndamax and the blood-thinning drug Eliquis. Pfizer's pipeline could bring even more big wins. A pill for COVID-19 may be on the way. The drugmaker also has more than 20 other late-stage programs. It is also adding to its portfolio through deals, including intentions to buy Trillium Therapeutics. Last, but not least, is Pfizer's dividend. Many income investors will like the dividend yield, which is currently 3.5%. For some investors, Pfizer stock looks like a good choice. But any endorsement for older Americans boosters isn't much of a factor in deciding whether or not to buy the stock one way or the other.
PShort
by FOREXN1
3
$PFE - Watch for bounce at $43 or fall to $40.71 before reversal$PFE is at critical junction. If it can hold $43 and reverse, it will have formed double bottome. If it fails to hold $43 we could see 40.71 before attempting reversal. Entries - $43 - $40 (trickle in) Target -$52 Stop loss (for chickens) OR double down! (for brave hearts!) - below - $38 ——————————————————— How to read my charts? - Matching color trend lines shows the pattern. Sometimes a chart can have multiple patterns. Each pattern will have matching color trend lines. - The yellow horizontal lines shows support and resistance areas. - Fib lines also shows support and resistance areas. - The dotted white lines shows price projection for breakout or breakdown target. Disclaimer: Do your own DD. Not an investment advice.
NYSE:PFELong
by PaperBozz
Pfizer dropping momentumFibgoals fractally at origin of Wave 5 of impulse and then beyond. If our mapping is correct, this impulse is done for now. Remember, this is not financial advice. You must do your own research and carefully make decisions for yourself by yourself. We love TA and do not provide individually tailored financial advice, or financial advice period. Now that aside, Fibonacci in crystal clear green and invalidation noted, as always, in red. Good luck out there.
NYSE:PFEShort
by Rykin_Capital